drugset / Trial / NCT00654706

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

NCT00654706

Phase 3 Completed 264 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.

Timeline

Start
2008-03
Primary completion
2010-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 400 mg Oral
Comparator Quetiapine Small molecule 500 mg Oral
Comparator Quetiapine Small molecule 600 mg Oral
Subject Sertindole Small molecule 12 mg Oral
Subject Sertindole Small molecule 16 mg Oral
Subject Sertindole Small molecule 20 mg Oral

Indications